Latest Breaking News On - Tim knotnerus - Page 1 : comparemela.com

Agomab Therapeutics NV: Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis

Agomab Therapeutics NV: Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Tim knotnerusGretchen schweitzerStefan klotterTrophic communicationsSingle ascending doseMultiple ascending doseChief development officerIdiopathic pulmonary fibrosisFibrostenosing crohnIdiopathic pulmonaryTransforming growth factorHepatocyte growth factorAgomab therapeuticsStephanie mayLassen sie

Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis

GHENT, Belgium, December 14, 2023 Agomab Therapeutics NV (‘Agomab’) today announced that it has dosed the first subject in a first-in-human Phase 1 clinical study of AGMB-447, an inhaled lung-restricted small molecule inhibitor of ALK5 (TGFβRI or ALK5). The study is evaluating AGMB-447 in healthy subjects and in patients with idiopathic pulmonary fibrosis (IPF).

Gretchen schweitzerTim knotnerusTrophic communicationsAgomab therapeuticsSingle ascending doseMultiple ascending doseChief development officerIdiopathic pulmonary fibrosisFibrostenosing crohnIdiopathic pulmonaryTransforming growth factorHepatocyte growth factorStephanie mayLung transplantLung diseasesBusiness wire

Agomab Therapeutics: Agomab Appoints Angelika Jahreis as Member of the Board of Directors and Andrea Sáez as Chief Development Officer

Agomab Therapeutics: Agomab Appoints Angelika Jahreis as Member of the Board of Directors and Andrea Sáez as Chief Development Officer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Paolo michieliTim knotnerusTorsten dreierGretchen schweitzerStefan klotterAngelika jahreisOsteoarthritis drug development workshopsUniversity of freiburgPompeu fabra universityDevelopment officerRegulatory affairsDevelopment unit head of immunology at novartisTrophic communicationsScripps research institute in la jollaSenior vice presidentDevelopment unit head

Agomab Appoints Angelika Jahreis as Member of the Board of Directors and Andrea Sáez as Chief Development Officer

Agomab Appoints Angelika Jahreis as Member of the Board of Directors and Andrea Sáez as Chief Development Officer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Tim knotnerusPaolo michieliAngelika jahreisGretchen schweitzerTorsten dreierDevelopment officerUniversity of freiburgPompeu fabra universityRegulatory affairsDevelopment unit head of immunology at novartisTrophic communicationsScripps research institute in la jollaOsteoarthritis drug development workshopsSenior vice presidentDevelopment unit headOrigo biopharma

Agomab Therapeutics NV: Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline

Agomab Therapeutics NV: Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Colleen cuffaroTim knotnerusFelice verduyn van weegenIyona rajkomarFidelity management research companyTrophic communicationsLife sciencesDawn biopharmaFibrostenosing crohnIdiopathic pulmonary fibrosisFelice verduynChief executive officerAgomab therapeuticsStephanie mayAktien sie